Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Gliomas and leukemias are difficult to treat, necessitating novel therapeutic approaches.
• Mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2), key enzymes in the tricarboxylic acid (TCA) cycle, are common in astrocytomas, glioblastomas, and acute myeloid leukemias.
• The exact molecular mechanisms by which IDH1/2 mutations contribute to tumorigenesis are not fully understood.

Purpose of the Study:

• To review recent advancements in understanding the oncogenic functions of IDH1/2 mutations.
• To elucidate the role of the oncometabolite R-2-hydroxyglutarate (R-2HG) in cancer development.
• To connect altered cancer cell metabolism to epigenetic modifications, RNA methylation, cellular signaling, hypoxic responses, and DNA repair.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of molecular mechanisms linking IDH1/2 mutations to cancer.
• Synthesis of information on the role of R-2HG in tumorigenesis.

Main Results:

• Gain-of-function IDH1/2 mutations promote the production of the oncogenic metabolite R-2HG.
• R-2HG inhibits α-ketoglutarate (αKG)-dependent enzymes, disrupting normal cellular functions.
• Altered metabolism due to IDH1/2 mutations influences epigenetics, RNA methylation, signaling, hypoxia response, and DNA repair.

Conclusions:

• IDH1/2 mutations and their product R-2HG are critical drivers of tumorigenesis in specific cancers.
• Understanding these metabolic and epigenetic alterations offers potential therapeutic targets.
• Further research is needed to fully characterize the complex interplay between metabolism, epigenetics, and cancer progression.